Clinical Trials Sponsored by Xenon Pharmaceuticals Inc

Total 4964 results

Xenon Pharmaceuticals Inc.

Terminated

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Australia, Belgium
Xenon Pharmaceuticals Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Healthy Volunteers

United Kingdom
Xenon Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Healthy Male Volunteers

United Kingdom
Xenon Pharmaceuticals Inc.

Completed

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Inherited Erythromelalgia | Primary Erythromelalgia

United States
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
Xenon Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

Major Depressive Disorder

United States
Xenon Pharmaceuticals Inc.

Completed

A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Acne Vulgaris

Canada
Xenon Pharmaceuticals Inc.

Completed

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Healthy Human Volunteers

Canada
Xenon Pharmaceuticals Inc.

Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Spain, Australia, Belgium, Italy
Xenon Pharmaceuticals Inc.

Completed

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Healthy Volunteers

United Kingdom
Xenon Pharmaceuticals Inc.

Completed

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Healthy Volunteers

United Kingdom
Xenon Pharmaceuticals Inc.

Completed

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) (XEN402)

Postherpetic Neuralgia

United States
Xenon Pharmaceuticals Inc.

Completed

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Dental Pain

United States
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials

Enrolling by invitation

An Open-label Study of XEN1101 in Epilepsy (X-TOLE4)

Focal Epilepsy | Tonic-Clonic Seizures

Spain, United States, Canada, Poland
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials

Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Focal Onset Seizures

United States, Spain, Italy, Croatia, Portugal, Poland, Chile, Argentina, Austria, Czechia
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

Primary Generalized Tonic-Clonic Seizures

United States, Australia, Bulgaria, Poland, Czechia, Canada, Portugal, Croatia, Italy, Spain
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials

Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2)

Focal Onset Seizures

United States, Spain, Australia, Poland, Canada, Bulgaria, Italy, United Kingdom
Xenon Pharmaceuticals Inc.
Novotech Health Holdings Pte. Ltd.

Active, not recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy (X-TOLE)

Focal Epilepsy

Spain, United States, Ukraine, Canada, United Kingdom, Germany, Georgia, Italy, Moldova, Republic of
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

cUTI

United States, Latvia, Poland, Czechia, Romania, Ukraine, Russian Federation, Georgia, Colombia, Bulgaria, Estonia, Greece, Hungary, Israel, Italy, Mexico, Moldova, Republic of, South Africa
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (IGNITE3)

Complicated Urinary Tract Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Hungary, Austria, Slovakia, Latvia, Moldova, Republic of, Georgia
Tetraphase Pharmaceuticals, Inc.

Completed

A Safety and PK Study of IV Eravacycline

Bacterial Infections

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

Chronic Idiopathic Constipation

United States
Anchen Pharmaceuticals, Inc
Novum Pharmaceutical Research Services

Completed

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

Osteo Arthritis of the Knee

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia

Clinical Trials Sponsored by Xenon Pharmaceuticals Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations